Replies to post #209997 on Biotech Values

[mcbio]

CTMX -

CytomX will also be eligible to receive up to $448 million in future development, regulatory and sales milestone payments for each collaboration target, as well as tiered royalties from the mid-single digits to low-double digits on net sales of each product commercialized by Bristol-Myers Squibb.

I don't really understand why CTMX can't negotiate for royalties that start at low double-digit rather than mid-single digit. Kind of disappointing to me. Nonetheless, I'm still impressed with all of their various partnerships in the IO space and I do have them on my list to potentially consider for the future.